2seventy bio, Inc. (TSVT) Tops Q1 EPS by 18c May 7, 2025 06:09PM
2seventy bio, Inc. (TSVT) Misses Q4 EPS by 17c Mar 25, 2025 04:48PM
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating 2seventy bio, Inc. Buyout Mar 11, 2025 04:43PM
2seventy bio (TSVT) Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb Mar 10, 2025 10:17PM
2Seventy Bio Inc. (TSVT) PT Lowered to $9 at Citi Feb 6, 2025 04:10PM


Feb 6, 2025 07:04AM 2seventy bio (TSVT) Reports Preliminary Full-Year U.S. Abecma Sales
Nov 12, 2024 12:52PM Goldman Sachs Reiterates Sell Rating on 2Seventy Bio Inc. (TSVT)
Nov 12, 2024 07:04AM 2seventy bio, Inc. (TSVT) Reports In-Line Q3 EPS
Sep 26, 2024 07:23AM 2Seventy Bio Inc. (TSVT) PT Raised to $25 at Leerink Partners
Sep 25, 2024 06:13AM 2seventy bio (TSVT) Provides Update on KarMMa-9 Study, Previews Anticipated Strong Q3 Revenue
Aug 7, 2024 07:10AM 2seventy bio, Inc. (TSVT) Tops Q2 EPS by 121c
Jun 26, 2024 04:11PM 2seventy bio (TSVT) Completes $40M Deal to Sell Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk (NVO)